HIT Consultant
APRIL 8, 2024
What You Should Know: – Model N (NYSE: MODN), a leading provider of revenue optimization and compliance solutions for the life sciences and high-tech industries, has announced a definitive agreement to be acquired by Vista Equity Partners (“Vista”). per share in an all-cash transaction valued at approximately $1.25
Healthcare ECONOMIST
MAY 30, 2023
Some policymakers have called for weakening of intellectual property protections for vaccines and other pharmaceutical products, with the aim to reduce the price and improve access to existing medical technologies, particularly in Eastern Europe and developing countries. The abstract is below.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Healthcare ECONOMIST
DECEMBER 28, 2022
 In the context of this fast-moving political debate, FTI Consulting supported INTERPAT, a non-profit biopharmaceutical consortium, and the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) in developing a White Paper and peer-reviewed article on the role of IP in the biopharmaceutical sector.
Health Populi
APRIL 6, 2022
For wonky-tech readers, this involves using Seqster’s proprietary technology (FHIR+) to enable the flow of patient information from once-siloed data locked into legacy systems and wearable tech clouds.
HIT Consultant
SEPTEMBER 1, 2021
With this in mind, it is critical that both payers and providers in VBC arrangements consider how their data flows through the entire system so that key partners, such as life sciences and pharmaceutical companies – have real-world insights (RWI) about the impact their medication is having on outcomes.
Health Populi
APRIL 1, 2022
To innovate more, and more quickly, across the entire ecosystem of health — in government policies, pharmaceutical innovations, and technology developments. To scale what works, based on evidence and proven interventions — which depends on our reducing biases in our assumptions, models and strategies.
Healthcare Leadership Council
NOVEMBER 17, 2022
It was acknowledged that not all that long ago the United States not the world’s global leader in life sciences, as it is today. All petitions using this theory have been rejected by multiple administrations, because it is not what the Bayh-Dole authors intended.
Expert insights. Personalized for you.
52 
Let's personalize your content